Μάλτα - Αγγλικά - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - influenza vaccine, split virion, inactivated - suspension for injection in pre-filled syringe - influenza vaccine (split virion, inactivated) a/victoria/4897/2022 (h1n1) pdm09 - like strain (a/victoria/4897/2022 ivr-238 15 µg a/thailand/8/2022 (h3n2)-like strain (a/california/122/2022, san-022) 15 µg b/austria/1359417/2021-like strain (b/michigan/01/2021, wild type) 15 µg b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type) 15 µg - vaccines

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

seqirus s.r.l. - a/guangdong-maonan/swl 1536/2019 (h1n1)pdm09-like strain (a/guangdong-maonan/swl 1536/2019, cnic-1909); a/hong kong/2671/2019 (h3n2)-like strain (a/hong kong/2671/2019, ivr-208); b/washington/02/2019-like strain (b/washington/02/2019, wild type) - suspension for injection in pre-filled syringe - . - influenza vaccines; influenza, inactivated, split virus or surface antigen - influenza vaccine - prophylaxis of influenza, especially in those who run an increased risk of associated complications

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

split virion, inactivated) high dose suspension for injection 0.5ml pre-filled syringes (sanofi pasteur - influenza virus inactivated split (h1n1, h3n2-like, b/brisbane/60/2008-like, strains) - suspension for injection

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus inactivated, containing antigen equivalent to a/california/07/2009 (h1n1)-derived strain used nymc x-179a - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1)v 2009 virus. pandemrix should only be used if the recommended annual seasonal trivalent / quadrivalent influenza vaccines are not available and if immunisation against (h1n1)v is considered necessary (see sections 4.4 and 4.8).pandemrix should be used in accordance with official guidance.

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

seqirus gmbh - influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain(a/brisbane/10/2010, wild type)a/switzerland/9715293/2013 (h3n2) - like strain(a/south australia/55/2014, wild type)b/phuket/3073/2013–like strain(b/utah/9/2014, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza for adults, especially in those who run an increased risk of associated complications.optaflu should be used in accordance to official guidance.

Καναδάς - Αγγλικά - Health Canada

id biomedical corporation of quebec - haemagglutinin from a/california/7/2009 (h1n1)v-like strain (x-179a) - suspension - 15mcg - haemagglutinin from a/california/7/2009 (h1n1)v-like strain (x-179a) 15mcg - vaccines

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

seqirus vaccines ltd - influenza virus surface antigens - suspension for injection

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

sanofi pasteur s.a. - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of idflu should be based on official recommendations.

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

sanofi pasteur europe - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of intanza should be based on official recommendations.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; monobasic sodium phosphate; octoxinol 9; dibasic sodium phosphate - fluquadri is indicated for active immunisation of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine.,fluquadri is indicated for use in adults and children 6 months and older.